This finding supports the role of STYK1 in modulating the sensitivity of NSCLC cells to EGFR TKI and suggests that expression levels of STYK1 could be a valuable biomarker to predict the long-term efficacy of EGFR TKI. This evidence concerns the gene EGFR and non-small cell lung carcinoma.